HepC – Superinfection is led by a seasoned executive team, with proven expertise in corporate management, business operations, drug discovery and drug development. HepC – Superinfection intends to keep its management and workforce streamlined and efficient. Its team of highly capable and proven business and scientific management personnel is planned to be broadened by adding operational personnel only in essential functions in the near term.

Tamas Bakacs, MBA
Chief Executive Officer

Mr. Tamas Bakacs, MBA, is an experienced Portfolio Manager and Corporate Finance professional with a demonstrated history of working in the financial services industry; specialist in the areas of commodity linked equity investments, biotechnology startups, private equity and real estate investments.  Mr. Bakacs founded his own corporate finance advisory business, Snow Leopard Capital Management Ltd., which provides tailored corporate finance advice to startup, small capitalization and middle market businesses regarding mergers and acquisitions, leveraged and management buyouts, debt restructuring and private placements of debt and equity. Previously, Mr. Bakacs was a global equity portfolio manager in Budapest, Hungary, in Edinburgh, UK., and in Almaty, Kazakhstan, where he managed various global equity investment funds, all specializing in the commodity sector or in natural resource based investments. Mr. Bakacs holds a B.S. in Accounting, Summa Cum Laude, from St. Francis College in New York and an MBA from the UCLA Anderson School of Management. In addition, he is also a member of the Advisory Board of Skyharbour Resources Ltd., a Canadian uranium exploration and development company listed on the TSX.v venture exchange.

Tibor Bakacs, MD, PhD, DSc
Chief Scientific Officer

Dr. Bakacs has 40 years of experience in scientific research. His current interests are (i) viral superinfection treatment (SIT) of hepatitis B and C virus infected patients with unmet needs; (ii) oncolytic Newcastle Disease virus (NDV) therapy of advanced cancer; (iii) therapeutic application of autoimmune T-cells, which are induced by an off-label low-dose immune checkpoint blockade in advanced cancer. Formerly, he was the Head of Immunology at the Hungarian National Institute of Oncology. He spent longer periods abroad, at the Karolinska Institute in Stockholm, Sweden, Christie Hospital in Manchester, UK and the National Cancer Institute (NCI/NIH) in the USA. Currently, he is the Chief Scientific Officer of Superinfection, Pret Therapeutics Ltd, and Lodoco Clinical Ltd. He is consultant at the Department of Probability, Alfred Renyi Institute of Mathematics. Dr. Bakacs authored 75 scientific papers and two patents.

Imre Kovesdi, PhD
Chief Operating Officer

Dr. Kovesdi has over 25 years of experience in the development of therapeutic drugs in both large pharmaceutical and biotechnology environments. He served as Chief Scientific Officer for 10 years at GenVec Inc. (NASDAQ:GNVC). He was responsible for the integration of key scientific advances and business objectives. Prior to joining GenVec, he led infectious disease projects at the Medical Research Division of the New York-based American Cyanamid Company for six years. As President of KILA Consulting LLC., he established several business collaborations between biotechnology companies and institutions. Dr. Kovesdi is creative strategist able to see the broader scientific and business needs and break them down to specific programs and projects, and direct them to completion. He is versatile facilitator, skilled at developing preclinical, clinical and licensing partnerships, able to identify foundation solutions to major health issues. He holds a Ph.D. in molecular biology and a degree in electrical engineering. He is the holder of over 100 US and foreign patents and has authored over 130 scientific articles. Dr. Kovesdi serves on the boards of a number of biotechnology and information technology companies.

Alena Lizonova, PhD
Advisor for Product Development
Alena Lizonova is an Analytical Sciences and Quality Control Director with over 25 years experience in discovery, development and quality control of therapeutic drugs in both large pharmaceutical and biotechnology environments. Dr. Lizonova is highly experienced in personal relations, directing numerous employees at all levels and interacting with contract testing and manufacturing organizations. She is skilled at developing solutions, organizational problems and handling budgets. She published over 40 technical papers and is a holder of 12 US and international patents.

Paul A. Stolk

Paul Stolk arrived in the early nineties as a student in technology from Holland. His curiosity to see new cultures and market developments made him stay in Hungary. His passion is to get from an idea to a workable company that has a base to grow and further develop. Until now he managed successful start-ups in the pharmaceutical-, communication- and information technology- industry.
Next to the last 20 years of international investment management and business development experience he has proven his expertise on transforming concepts into products (e.g. Despharma product range– product being sold in 55 countries worldwide www.dermalex.co.uk).
Next to his work he is an active board member of the Dutch Hungarian chamber of commerce (www.dutcham.hu). In his free time he spends time with his wife and three daughters, sailing, golf and mountain biking.
Prof. Shimon Slavin, MD
The Medical Director
Shimon Slavin, MD, is an Israeli professor of medicine. Dr. Slavin pioneered the use of immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation for the cure of hematological malignancies and solid tumors, and using hematopoietic stem cells for the induction of transplantation tolerance to bone marrow and donor allografts. More recently, he’s been working on the use of multi-potent mesenchymal stem cell (MSC) for regenerative medicine for the treatment of neurological, systemic, and orthopedic disorders. Dr. Slavin is an author of 4 books, his basic research and clinically applied discoveries were represented in over 600 published articles and more than 900 national and international scientific presentations, which resulted in international impact in several different disciplines mostly related to cellular therapy for treatment of malignant and nonmalignant disorders. Immunotherapy of cancer by donor lymphocytes made it possible to treat otherwise resistant hematological malignancies and certain metastatic solid tumors in patients with multidrug resistant cancer. At present, Slavin operates his new clinic, Biotherapy International, The Center for Innovative Cancer Biotherapy & Regenerative Medicine in Tel Aviv, Israel.